Choose Health Launches Most Comprehensive At-Home Liver Function Test with 20+ Biomarkers and Clinical Risk Scores

Choose Health launched an at-home Comprehensive Liver Function Test measuring 20+ liver and metabolic markers, targeting MASLD/fatty liver disease affecting ~33% of U.S. adults (with most undiagnosed). The test uses a finger-prick sample and returns physician-reviewed results in days, with state availability in 48 states (excluding NY and RI). The company highlights guideline-based reversal potential (3–5% weight loss for steatosis; >10% for steatohepatitis/fibrosis), positioning the product to expand screening rather than provide diagnosis.

Analysis

The incremental winner is not the test vendor so much as the downstream care stack. If screening lowers friction, the monetization migrates to labs, primary-care follow-up, GLP-1 prescribers, and chronic-metabolic programs; that argues more for LLY/NVO and integrated care platforms than for a standalone consumer diagnostics name. The first-order revenue pool is likely small, but the second-order pool is recurring: repeat monitoring, treatment initiation, and longer-duration patient management.

The main risk is that this becomes a one-and-done awareness product rather than a durable testing habit. At-home collection has obvious convenience advantages, but conversion depends on reimbursement, physician follow-through, and a clear therapeutic path; without those, gross margins can be fine while LTV/CAC remains unattractive. The state exclusions also matter: regulatory fragmentation is a reminder that scaling nationally may require more compliance spend than the release implies.

Contrarian view: the market may be overestimating the diagnostic TAM and underestimating the treatment funnel. MASLD is a screening story only if it reliably drives action; otherwise it is just another low-frequency consumer test with limited repeat demand. Over 6-18 months, the real proof point is whether screening cohorts show measurable uptake in GLP-1s, weight-loss programs, or follow-up lab cadence; absent that, the announcement is more marketing than earnings catalyst.

Key Decisions for Investors

• No immediate equity trade on the release itself; treat it as a watch item until there is evidence of reimbursement, repeat testing, or conversion into treatment starts.
• Over the next 1-3 months, monitor LH and DGX for any consumer-testing volume commentary; only consider a tactical long if management quantifies incremental high-margin volume rather than promotional noise.
• For a thematic expression, favor a conditional long LLY/NVO on evidence that screening is lifting GLP-1 initiation rates; the thesis fails if new-patient starts do not improve over the next 2-3 quarters.
• Avoid shorting consumer health or diagnostics here; the signal is too small and the likely economic benefit is diffuse, making the payoff unattractive versus carry and event risk.